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Aspergillus is damaged by polymorphonuclear neutrophils (PMNs) by means of nonoxidative and oxidative
mechanisms, which may be affected by antifungal and antibacterial agents that patients with invasive pulmo-
nary aspergillosis often receive. The pharmacodynamic interactions among deoxycholate amphotericin B
(AMB), ciprofloxacin (CIP), and human PMNs against Aspergillus fumigatus growth are unknown. We therefore
studied the interactions between 0.032 to 2.0 g/ml of AMB, 0.1 to 50 g/ml of CIP at a fixed AMB/CIP ratio
of 1:3.125, and PMNs from six donors at an effector-to-target (E:T) ratio of 400:1 against a clinical A. fumigatus
isolate using an XTT metabolic assay and the Bliss independence pharmacodynamic-interaction model. CIP
exhibited no antifungal activity alone or in combination with PMNs. Synergy was found between AMB and
PMNs, with interaction indices (II) of 0.06 to 0.21; the highest interaction of 21%  3.6% was observed at
0.22  0.09 g/ml of AMB. The AMB and CIP (AMBCIP) combination was synergistic (II  0.39) at low
AMB concentrations and antagonistic (II  1.39) at high AMB concentrations, with a maximal synergistic
interaction of 16%  3.7% observed at 0.16  0.08 g/ml of AMB. The triple combination AMBCIPPMNs
was synergistic, with interaction indices of 0.05 to 0.20, and a maximal synergistic interaction of 24% 4% was
observed at 0.20  0.07 g/ml of AMB. The increased percentage of Bliss synergy of the triple combination
AMBCIPPMNs (24% 4%) was the product of those of the constituent double combinations AMBPMNs
(21%  3.6%) and AMBCIP (16%  3.7%). Thus, the antifungal activity of AMB, at clinically relevant
concentrations, was enhanced in combination with PMNs and CIP against A. fumigatus growth in a concen-
tration-dependent manner.
Aspergillus spp. are common pathogens causing life-threat-
ening, invasive fungal disease in immunocompromised patients
(21, 26). Patients at risk for invasive aspergillosis are also at
risk for the development of bacterial infections, for which
fluoroquinolones may be used for prophylactic and therapeutic
purposes concomitantly with antifungal agents, such as ampho-
tericin B (AMB) (1, 13). Although fluoroquinolones have no
intrinsic antifungal activity, high levels of topoisomerases, the
targets of fluoroquinolones, have been reported in pathogenic
fungi (18). Ciprofloxacin (CIP), a fluoroquinolone, was previ-
ously found to interact pharmacodynamically with antifungal
agents by altering their growth-inhibitory activities against
Candida albicans and Aspergillus fumigatus (22).
Polymorphonuclear neutrophils (PMNs) are important com-
ponents of the innate host defense against invasive aspergillo-
sis (4). Oxidative pathways are among the main antifungal
mechanisms of PMNs that are involved in hyphal damage (17).
During the oxidative burst, activation of NADP (NADPH)
oxidase results in the production of a superoxide anion (O2
),
a reactive oxygen intermediate that is released. Both ampho-
tericin B and ciprofloxacin exert immunomodulating activity
on human immunocompetent cells, affecting humoral and cel-
lular immunity (5, 6, 20).
In this study, we investigated the interactions between hu-
man PMNs, ciprofloxacin, and deoxycholate AMB. Each of the
agents listed has distinct mechanisms of action. The Bliss in-
dependence no-interaction theory is based on the probability
law of independent events and can be used to analyze phar-
macodynamic interactions among such agents that have inde-
pendent actions (12). We therefore analyzed the pharmacody-
namic interactions among AMB, ciprofloxacin, and PMNs
against A. fumigatus with the Bliss independence no-interac-
tion theory.
MATERIALS AND METHODS
Isolates and medium. The A. fumigatus 4215 (ATCC MYA-3626) strain was
used in this study. The strain was stored on potato dextrose agar slants at 70°C.
Aspergillus conidia were collected with a wet swab from 5- to 7-day-old cultures
in Sabouraud dextrose agar. Conidial suspensions were adjusted spectrophoto-
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metrically at 530 nm to 80 to 82% transmittance and diluted in order to obtain
two times the final inoculum, which ranged from 0.4  104 to 5  104 CFU/ml
(this range was chosen based on CLSI guidelines) in the medium, which
consisted of RPMI 1640 medium buffered at pH 7 with 0.165 M MOPS
(morpholinepropanesulfonic acid) (BioWhittaker, Walkersville, MD). Can-
dida parapsilosis (ATCC 22019), Candida krusei (ATCC 6258), A. fumigatus
(ATCC MYA-3626), and Escherichia coli (ATCC 259222) were used as qual-
ity controls.
Antimicrobial compounds and combination microtitration plates. Ciprofloxa-
cin (Bayer AG, Leverkusen, Germany) and AMB (Ben Venue Laboratories,
Inc., Bedford, OH) stock solutions were prepared according to the manufactur-
ers’ guidelines and diluted in the assay medium in order to obtain working
solutions of 200 g/ml and 8 g/ml, respectively. Amphotericin B and ciprofloxa-
cin were serially diluted 2-fold in the medium in order to obtain four times the
final concentrations, which ranged from 0.032 to 2.0 g/ml and from 0.1 to 50
g/ml, respectively. The combination of AMB with ciprofloxacin at a fixed ratio
of 1:3.125 was prepared by 2-fold serial dilutions of a combination of 2 g/ml
AMB and 6.25 g/ml CIP. This fixed ratio is usually observed in vivo because the
maximum concentration in serum (Cmax) of ciprofloxacin after a dosage of 400
mg every 12 h (q12h) intravenously (i.v.) is approximately three times higher than
the Cmax of AMB after a dosage of 1 mg/kg of body weight (2, 25). All experi-
ments were performed in 96-well flat-bottom microtitration plates (Corning Inc.,
Corning, NY). The plates were stored at 70°C and thawed on the day of
experiment.
Preparation of PMNs. Elutriated human PMNs from six healthy adult volun-
teers were obtained from the Department of Transfusion Medicine, National
Institutes of Health, Bethesda, MD. They were further processed with 5% dex-
tran solution (Pharmacis Fine Chemicals, Piscataway, NJ) for sedimentation of
excess erythrocytes. Contaminating erythrocytes were lysed by suspension of the
neutrophilic pellet in distilled water for 15 to 20 s, followed by the addition of
hypertonic saline to correct the tonicity of the solution. PMNs were finally
suspended in Hanks’ balanced salt solution without Ca2 and Mg2. The via-
bility of the PMNs was tested by the trypan blue exclusion method. PMNs were
added into the wells at an effector-to-target (E:T) ratio of 400:1 before the
inoculation. Different E:T ratios were tested, ranging from 1:1 to 800:1, in order
to choose the E:T ratio that resulted in approximately 50% of fungal growth,
which would allow us to detect both synergy and antagonism. E:T ratios resulting
in very small and very large percentages of growth would not be able to detect
antagonistic and synergistic interactions, respectively.
XTT colorimetric assay. After incubation of microtitration plates containing
the agents alone and in double and triple combinations for each donor at 37°C
for 24 h, the growth in each well was determined with the XTT assay by mea-
suring the fungal-biomass-associated metabolic activity (10). One hundred mi-
croliters of XTT-menadione solution was added to each well in order to obtain
final concentrations of 100 g/ml XTT-25 M menadione. XTT conversion by
viable hyphae was measured at 450 nm. The percentage of fungal growth was
calculated for each concentration with the equation (A450 of a well  background
A450)/(A450 of the drug-free well  background A450 of the drug-free well) 
100%, where the background A450 was measured from a plate inoculated with a
conidium-free inoculum.
Pharmacodynamic interaction analysis. The interactions within the double
and triple combinations of AMB (0.03 to 2 g/ml), ciprofloxacin (at a 1:3.125
fixed ratio with AMB), and PMNs (at an E:T ratio of 400:1) were analyzed with
the Bliss independence zero-interaction theory. Based on this pharmacodynamic
theory, if three agents, A, B, and C, do not interact, they act independently and
the effects of their joint actions should follow the probability law of independent
events (15). This effect derives from the equation IIND  I  I, where IIND is
the growth inhibition of a Bliss independence combination and I and I are the
summation and the product, respectively, of growth inhibitions (Is) of each
constituent agent alone and in combination [i.e., IIND  (IA  IB  IC)  (IA 
IB)  (IA  IC)  (IB  IC)  (IA  IB  IC)]. The latter equation can be
simplified by replacing I with 1  E, where E is the percentage of fungal growth.
Thus, the Bliss independence effect can be calculated by the equation EIND 
EAMB  ECIP  EPMN, where EAMB, ECIP, and EPMN are the percentages of
growth with AMB, ciprofloxacin, and PMNs alone, respectively, and EIND is the
theoretical percentage of growth if the constituting agents of the combinations
acted independently.
For each double and triple combination, the theoretical Bliss independence
concentration-effect data were calculated using the above-mentioned equation
and analyzed with nonlinear-regression analysis based on the sigmoid curve
with variable slope described by the equation E  B  Emax  B	
/
1  10logEC50  logC	  m, where E is the percentage of growth (dependent
variable) at the drug concentration C (independent variable), Emax is the maximum
percentage of growth observed in the drug-free control (i.e., 100%), B is the mini-
mum percentage of growth at an infinite drug concentration (i.e., 0%), EC50 is the
effective drug concentration producing 50% of the Emax, and m is the slope of the
concentration-effect curves (Hill coefficient) (Prism 5.0; GraphPad Inc.).
Pharmacodynamic interactions were determined at three different effective
levels, the EC10, EC50, and EC90, which are drug concentrations corresponding
to 10, 50, and 90% of growth, respectively. These three ECs describe interactions
at high, medium, and low drug concentrations, relative to the MIC (the EC10 is
close to the MIC, and the EC90 is much lower than the MIC). The EC50 was
derived directly from the sigmoid equation, whereas the EC10 and EC90 were
estimated based on the EC50 solving the sigmoid equation for log C and by using
10% and 90%, respectively, as E. The experimentally observed effective concen-
trations (ECOBS) were compared with the theoretical Bliss independence effec-
tive concentrations (ECIND) for each combination. The interaction indices of
EC10,OBS/EC10,IND, EC50,OBS/EC50,IND, and EC90,OBS/EC90,IND were then cal-
culated, and synergy or antagonism was concluded when these indices were
significantly lower or higher than 1, respectively, based on their 95% confidence
interval; if this interval included 1, Bliss independence was concluded.
Finally, the magnitudes and AMB concentrations of Bliss interactions within
the double and triple combinations were compared. The percentage of Bliss
interactions at each AMB concentration was calculated by subtracting the ex-
perimental percentage of growth from the theoretical percentage of growth and
analyzed with nonlinear-regression analysis using the bell-shaped curve de-
scribed by the equation E  Emax  e0.5
logClogCmax)/SD
2 , where E is the
percentage of the Bliss interaction, Emax is the maximal percentage of the Bliss
interaction, C is the concentration of AMB, Cmax is the AMB concentration of
Emax, and the standard deviation (SD) is a measure of the widths of Bliss
interactions (Prism 5.0; GraphPad Inc.). The Emaxs, Cmaxs, and SDs of the
double and the triple combinations were then compared using a one-way analysis
of variance (ANOVA).
RESULTS
Effects of single compounds. The MIC of AMB was 0.5
g/ml against A. fumigatus, with its antifungal activity following
a sigmoidal concentration-effect curve (EC50  0.51 g/ml,
m4.2, R2  0.85), as shown in Fig. 1. PMNs alone resulted
in fungal growth of 39%  6% at the E:T ratio of 400:1,
whereas CIP alone resulted in fungal growth of 97%  5% for
the entire range of CIP concentrations.
Effect of the combination AMBPMNs. The double combi-
nation of AMB and PMNs (AMBPMNs) for all donors fol-
lowed a sigmoidal concentration-effect relationship (EC50 
0.38 g/ml, m  1.9, R2  0.80) that, however, shifted to the
left, signifying Bliss synergy, and was shallower than the con-
centration-effect relationship of AMB alone. The combination
AMBPMNs was Bliss synergistic, with interaction indices of
0.06 at the EC90 and 0.21 at the EC50 (Table 1). At the EC10
(the drug concentration close to the MIC), the interaction
index was lower than 1 but not by a statistically significant
amount. The Bliss synergistic interactions followed a bell-
shaped curve (SD  0.40) spanning from log Cmax minus the
SD to log Cmax plus the SD (i.e., 0.09 to 0.56 g/ml of AMB,
with the maximal synergistic interaction of an Emax of 21% 
3.6% being observed at an AMB Cmax of 0.22  0.09 g/ml)
(Fig. 2).
Effect of the AMBCIP combination. The concentration-
effect relationship of the double combination AMBCIP is
shown in Fig. 3. CIP did not have significant antifungal activity,
since its concentration-effect curve was a line parallel to the x
axis, as shown in Fig. 4. The concentration-effect relationship
of the AMBCIP combination was shifted to the left at low
AMB concentrations, indicating Bliss synergy (interaction in-
dex of 0.39), and to the right of the concentration-effect rela-
tionship of AMB alone at higher AMB concentrations, indi-
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cating Bliss antagonism (interaction index of 1.39) (Table 1);
however, this effect was significantly different from Bliss inde-
pendence. The Bliss synergistic interactions also followed a
bell-shaped relationship spanning from 0.06 to 0.39 g/ml of
AMB (SD  0.4), with a maximal synergistic interaction at an
Emax of 16%  3.7% observed at a Cmax of 0.16  0.08 g/ml
of AMB (Fig. 2).
Effect of the combination CIPPMNs. The concentration-
effect relationship of the double combination CIPPMNs is
shown in Fig. 4. Ciprofloxacin did not have any direct antifun-
gal activity and did not alter the antifungal activity of PMNs.
Effect of the triple combination AMBCIPPMNs. The
antifungal activity of the triple combination AMBCIP
PMNs was described by a sigmoidal concentration-effect rela-
tionship (EC50  0.10 g/ml, m  1.5, R
2  0.64) that was
shifted to the left, signifying Bliss synergy, and was shallower
than the theoretical Bliss independence concentration-effect
curve (Fig. 5). Bliss synergy was observed with interaction
FIG. 1. Double combination of amphotericin B (AMB) and polymorphonuclear cells (PMNs). Concentration-effect data and regression curves
for AMB alone, PMNs alone, the double combination AMBPMNs at an E:T ratio of 400:1, and the Bliss independence theoretical combination
AMBPMNs if AMB and PMNs act independently. Error bars represent standard errors among 2 replicates and 6 donors. Bliss synergy was found
between AMB and PMNs, as the experimental curve (dashed black line) is shifted to the left of the theoretical (dashed gray line) concentration-
effect curve of AMBPMNs (i.e., a lower percentage of growth was obtained when AMB was combined with PMNs than was obtained by the
theoretical combinations). The open triangle next to the y axis corresponds to 0 g/ml of AMB, but it was shifted to the right for visualization
purposes.
TABLE 1. Bliss independence interaction analysis of double and triple combinations of AMB, CIP, and PMNsa
Combination Endpoint Exptl ECOBS (g/ml)(95% CI)
Theoretical ECIND
(g/ml) (95% CI)
Interaction
index Interpretation
AMBCIP EC90 0.11 (0.09–0.14) 0.29 (0.25–0.32) 0.39
b Synergy
EC50 0.37 (0.3–0.44) 0.5 (0.45–0.57) 0.74 Synergy
EC10 1.23 (1.01–1.51) 0.88 (0.78–1.01) 1.39
b Antagonism
AMBPMN EC90 0.02 (0.01–0.03) 0.31 (0.24–0.39) 0.06
b Synergy
EC50 0.11 (0.06–0.19) 0.51 (0.41–0.65) 0.21
b Synergy
EC10 0.68 (0.38–1.2) 0.87 (0.69–1.09) 0.78 Independence
AMBCIPPMN EC90 0.01 (0.01–0.03) 0.29 (0.22–0.36) 0.05
b Synergy
EC50 0.1 (0.06–0.18) 0.5 (0.39–0.64) 0.20
b Synergy
EC10 0.71 (0.41–1.22) 0.89 (0.7–1.14) 0.80 Independence
a The double combinations AMBCIP and AMBPMN and the triple combination AMBCIPPMN were analyzed by Bliss independence interaction analysis.
The double combination of CIPPMN was not analyzed because no effect was observed at any concentration of CIP. CI, confidence interval.
b Significantly smaller than 1 (P  0.05).
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indices of 0.05 at the EC90 and 0.20 at the EC50 (Table 1),
whereas Bliss independence was found at higher AMB con-
centrations corresponding to the EC10. Bliss synergistic inter-
actions followed a bell-shaped relationship (Fig. 2) spanning
from 0.08 to 0.48 g/ml of AMB (SD  0.38), with the maximal
synergistic interaction of 24%  4% observed at 0.20  0.07
g/ml of AMB. There are no significant differences among the
maximal percentages of the Bliss synergistic interactions of the
triple combination AMBCIPPMNs (24%) and the double
combinations AMBPMNs (21%) and AMBCIP (16%)
(ANOVA P value of 0.05).
DISCUSSION
In this study, we demonstrated that conventional AMB
synergistically interacts with PMNs and CIP against A.
fumigatus growth in a concentration-dependent manner,
with maximal synergies of 21% and 16%, respectively, ob-
FIG. 2. Bliss synergistic interactions between amphotericin B (AMB), ciprofloxacin (CIP), and PMNs followed a bell-shaped curve, with the
maximal synergistic interactions of 21%  3.6%, 16%  3.7%, and 24%  3.9% being observed at 0.22  0.09, 0.16  0.08, and 0.20  0.07 g/ml
of AMB for the combinations AMBPMNs, AMBCIP, and AMBCIPPMNs, respectively. Bliss interaction curves were obtained by
subtracting the theoretical data from the experimental data for the six donors.
FIG. 3. Double combination of amphotericin B (AMB) and ciprofloxacin (CIP). Concentration-effect data and regression curves for AMB
alone, CIP alone, the double combination AMBCIP at a fixed ratio of 1:3.125, and the AMBCIP Bliss independence theoretical combination
if AMB and CIP act independently. Error bars represent standard errors among 6 replicates. Bliss synergy was found at low concentrations of
AMB, as the experimental curve (dashed black line) is to the left of the theoretical concentration-effect curve (gray line) of AMBCIP (i.e., a lower
percentage of growth was obtained when AMB was combined with CIP than was obtained by the theoretical combinations). At higher AMB
concentrations, the experimental curve is to the right of the theoretical concentration-effect curve of the AMBCIP combination, resulting in Bliss
antagonism. The open circle next to the y axis corresponds to 0 g/ml of AMB, but it was shifted to the right for visualization purposes.
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served at sub-MIC AMB concentrations. Ciprofloxacin did
not have any effect alone or in combination with PMNs
against A. fumigatus growth. The triple combination
AMBCIPPMNs was also synergistic, with a maximal syn-
ergistic interaction of 24%, which is higher than those of the
single constituent agents.
Bliss independence theory has been previously used to
adequately describe in vitro pharmacodynamic interactions
between antifungal agents, the results of which correlated
with in vivo results from experimental invasive pulmonary
aspergillosis (11, 14). Because Bliss independence theory is
based on independent events like the distinct modes of
action of the three agents investigated in the present study
(12), we report its first application, to our knowledge, to
describe the interaction between a systemic antifungal
agent, a fluoroquinolone with no direct antifungal activity,
and a nonchemotherapeutic agent like phagocytic cells.
Other advantages of Bliss independence theory are the facts
that it does not require full descriptions of concentration-
effect relationships and that it can be applied even when the
maximal and minimal responses are not the same among the
combined agents (12), e.g., the maximal-minimal effects
were 40 to 0%, 100 to 0%, and 100 to 0% of growth with
PMNs, AMB, and CIP, respectively.
Previous studies have reported that conventional AMB en-
hances PMN antifungal function at a concentration of 1 or 5
g/ml conventional AMB (6). In the present study, we inves-
tigated more comprehensively than in those studies the inter-
actions between conventional AMB and PMNs against A. fu-
migatus growth by using a broader range of AMB
concentrations achievable in plasma and a pharmacodynamic
theory for the detection of synergy. Unlike in previous studies
FIG. 4. Double combination of ciprofloxacin (CIP) and polymorphonuclear cells (PMNs). Concentration-effect data and regression lines of CIP
alone, PMNs alone, the double combination CIPPMNs, and the Bliss independence theoretical combination CIPPMNs if CIP and PMNs act
independently. Ciprofloxacin did not exhibit a direct effect on Aspergillus growth and did not significantly alter the antifungal activity of PMNs. The
open triangle next to the y axis corresponds to 0 g/ml of ciprofloxacin, but it was shifted to the right for visualization purposes.
FIG. 5. Triple combination AMBCIPPMNs. Concentration-effect data and regression curves for AMB alone and the effects of CIP and
PMNs alone, the triple combination AMBCIPPMNs, and the theoretical Bliss independence combination AMBCIPPMNs if all constituent
agents act independently from each other. Error bars represent standard errors among 2 replicates and 6 donors.
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(6, 7), the present experiments were conducted with the addi-
tion of agent to the conidia prior to the formation of germlings,
which increased the exposure time and, consequently, the ef-
fect.
There are several potential mechanisms for the enhanced
antifungal activities of AMB in combination with PMNs. AMB
may damage maturing Aspergillus conidia and hyphae and ren-
der them vulnerable targets for PMNs. Furthermore, it has
been previously shown that signaling through Toll-like recep-
tor 2 (TLR2) promotes the fungicidal activity of PMNs
through nonoxidative pathways involving the extracellular re-
lease of gelatinases and proinflammatory cytokines, while
TLR4 favors the oxidative pathways through the participation
of azurophil, myeloperoxidase-positive granules, and interleu-
kin 10 (IL-10) (3). AMB (16, 19) and ciprofloxacin (5) are
well-recognized immunomodulators affecting the production
of O2
, tumor necrosis factor alpha (TNF-), and proinflam-
matory and anti-inflammatory cytokines from innate host de-
fense cells. Thus, AMB may enhance the fungicidal activity of
PMNs through several mechanisms.
AMB was found to interact synergistically at low concentra-
tions of CIP and antagonistically at high concentrations of CIP.
This is in agreement with previous studies where the double
combination AMBCIP was synergistic at CIP concentrations
of 10.6 g/ml and antagonistic at CIP concentrations ap-
proaching 50 g/ml against Candida albicans and A. fumigatus
using isobolographic analysis (23). This similarity of findings
suggests that the findings of the Bliss model in the current
study are not due to methodological bias but that they are
probably related to certain biological factors that are unclear at
present. Ciprofloxacin molecules are zwitterionic and are pres-
ent as monomers at low concentrations, whereas at higher
concentrations, they are self-associated in a head-to-tail ar-
rangement (9). Given that ciprofloxacin molecules interact
with cholesterol-containing liposomes (9), ciprofloxacin at low
concentrations may participate in pore formation on fungal
cell membranes imposed by amphotericin B and may thereby
enhance its antifungal action. However, the self-association of
ciprofloxacin molecules at high concentrations may interfere
with amphotericin B pore formation, thereby decreasing its
antifungal activity and thus producing an antagonistic effect, as
found in the present study. This antagonistic effect is unlikely
to have clinical application, as serum ciprofloxacin concentra-
tions of 50 g/ml are not safely achieved with standard dosing
regimens. The study of variable concentration-dependent in-
teractions of drug combinations allows us to draw possible
conclusions regarding their pharmacodynamic effects in clini-
cal practice. These results may be clinically significant, because
the drug concentrations after the initial doses at the start of
therapy and the concentrations between sequential doses
thereafter alter gradually over time.
A potential mechanism of the triple synergistic interaction is
the increased AMBCIP antifungal activity, which may facil-
itate phagocytosis by PMNs. In addition, AMB has been found
to increase the uptake of CIP by PMNs (8), which may enhance
the antifungal activity of the triple combination inside PMNs.
In vivo combination studies have shown that the combination
of ciprofloxacin (4 mg/kg/day) with AMB (0.1 mg/kg) provides
significantly more protection to nonneutropenic mice infected
by C. albicans than AMB or ciprofloxacin alone (24). Of note,
ciprofloxacin (4 mg/kg/day) alone resulted in prolonged sur-
vival compared to the control, suggesting some immunomodu-
latory effect of this agent against candidiasis. Although it is
difficult to conclude if this was the result of pharmacodynamic,
pharmacokinetic, and/or immunological interactions, it seems
that CIP and AMB can interact synergistically in the presence
of neutrophils.
Of note, the combination of AMB and PMNs exhibited its
synergistic effect against A. fumigatus growth at sub- and near-
MIC concentrations (0.06 to 0.5 g/ml) that are readily
achieved in vivo. This suggests that PMNs may enhance the
antifungal activity of AMB at the areas of infection. Further-
more, the fact that AMB interacted synergistically with CIP
even in the absence of PMNs indicates that this combination
would still have good efficacy in neutropenic patients. In vivo
studies in experimental invasive aspergillosis are warranted to
investigate these interactions in vivo.
This study found that the Bliss independence model proved
to be a useful tool for assessing complex pharmacodynamic
and immunomodulatory interactions, such as those between
antifungal agents, nonantifungal compounds, and human phago-
cytes. We cannot draw direct clinical conclusions from just in
vitro results, since conditions in the human body are much
more complicated than those in in vitro experiments. By un-
derstanding what the situation is in vitro, however, we can
conduct in vivo studies and test our initial hypothesis. Further
animal studies are needed for better understanding of these in
vitro interactions.
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